Anti-GM-CSF Monoclonal Antibody (<strong>MOR103</strong>) in RA First in Patient Study of Anti-GM-CSF Monoclonal Antibody (<strong>MOR103</strong>) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo- Controlled Trial Frank Behrens 1 , Mikkel Ostergaard 2 , Rumen Stoilov 3 , Piotr Wiland 4 , Thomas W. Huizinga 5 , Vadym Y. Berenfus 6 , Paul-Peter Tak 7 , Stoyanka Vladeva 8 , Juergen Rech 9 , Andrea Rubbert-Roth 10 , Mariusz Korkosz 11 , Dmitriy Rekalov 12 , Igor A. Zupanets 13 , Bo J. Ejbjerg 14 , Jens Geiseler 15 , Julia Fresenius 15 , Roman P. Korolkiewicz 16 , Arndt J. Schottelius 16 and Harald Burkhardt 1 1 CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, 2 Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3 University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, 4 Wroclaw Medical University, Wroclaw, Poland, 5 Leiden University Medical Center, Leiden, Netherlands, 6 Regional Clinical Hospital, Donetsk, Ukraine, 7 Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, 8 Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, 9 University of Erlangen-Nuremberg, Erlangen, Germany, 10 University of Cologne, Cologne, Germany, 11 Malopolskie Centrum Medyczne, Krakow, Poland, 12 Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 13 Kharkiv, Ukraine, 14 Hospital at Slagelse, Slagelse, Denmark, 15 Asklepios Clinic Munich-Gauting, Gauting, Germany, 16 <strong>MorphoSys</strong> AG, Martinsried/Planegg, Germany ACR/ARHP 2012 – Washington DC – November 10-14, 2012
Disclosures • F. Behrens, M. Ostergaard, R. Stoilov, P. Wiland, T. W. Huizinga, V. Y. Berenfus, S. Vladeva, J. Rech, A. Rubbert-Roth, M. Korkosz, D. Rekalov, I. A. Zupanets, B. J. Ejbjerg, J. Geiseler, J. Fresenius, H. Burkhardt are investigators on the <strong>MOR103</strong> study • P. P. Tak was a consultant to <strong>MorphoSys</strong> AG and is employee of GlaxoSmithKline • R. P. Korolkiewicz and A. J. Schottelius are employees of <strong>MorphoSys</strong> AG • The study was sponsored by <strong>MorphoSys</strong> AG ACR/ARHP 2012 – Washington DC – November 10-14, 2012